Comparison of the risks of opioid abuse or dependence between tapentadol and oxycodone: Results from a cohort study

Journal of Pain

Volumn 14, Issue 10, 2013, Pages 1227-1241

  Cepeda, M Soledad ^a   Fife, Daniel ^a   Ma, Qianli ^a   Ryan, Patrick B ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

cohort studies; opioid abuse; opioid dependence; Opioids; oxycodone; tapentadol

Indexed keywords

BENZODIAZEPINE;

ADULT; ARTICLE; COHORT ANALYSIS; DRUG DEPENDENCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; OXYCODONE ADDICTION; RISK FACTOR; TAPENTADOL ADDICTION;

COHORT STUDIES; OPIOID ABUSE; OPIOID DEPENDENCE; OPIOIDS; OXYCODONE; TAPENTADOL;

ADULT; AGED; ANALGESICS, OPIOID; COHORT STUDIES; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; MIDDLE AGED; ODDS RATIO; OPIOID-RELATED DISORDERS; OXYCODONE; PAIN; PHENOLS; PROPENSITY SCORE; RETROSPECTIVE STUDIES; RISK; SAMPLE SIZE;

EID: 84885021096     PISSN: 15265900     EISSN: 15288447     Source Type: Journal    
DOI: 10.1016/j.jpain.2013.05.010     Document Type: Article

References (44)

1. American Academy of Pain Medicine, American Pain Society, American Society of Addiction Medicine. Definitions related to the use of opioids for the treatment of pain: consensus statement. http://www.asam org/advocacy/find-a- policy-statement/view-policy-statement/public-policy-statements/2011/12/15/ definitions-related-to-the-use-of-opioids-for-the-treatment-of-pain-consensus- statement 2001
2. R. Buynak, D.Y. Shapiro, A. Okamoto, I.V. Hove, C. Rauschkolb, A. Steup, B. Lange, C. Lange, and M. Etropolski Efficacy and safety of tapentadol extended release for the management of chronic low back pain: Results of a prospective, randomized, double-blind, placebo- and active-controlled phase III study Exp Opin Pharmacother 11 2010 1787 1804
3. CDC grand rounds: Prescription drug overdoses - A U.S. epidemic MMWR Morb Mortal Wkly Rep 61 2012 10 13
4. M.S. Cepeda, M. Etropolski, R. Weinstein, D. Fife, R. Boston, and A. Matcho Dose patterns in commercially insured subjects chronically exposed to opioids: A large cohort study in the United States BMC Palliat Care 9 2010 14
5. M.S. Cepeda The use of propensity scores in pharmacoepidemiologic research Pharmacoepidemiol Drug Saf 9 2000 103 104
6. M.S. Cepeda, R. Boston, J.T. Farrar, and B.L. Strom Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders Am J Epidemiol 158 2003 280 287
7. M.S. Cepeda, D. Fife, W. Chow, G. Mastrogiovanni, and S.C. Henderson Assessing opioid shopping behaviour: A large cohort study from a medication dispensing database in the US Drug Saf 35 2012 325 334
8. M.S. Cepeda, D. Fife, W. Chow, G. Mastrogiovanni, and S.C. Henderson Opioid shopping behavior: How often, how soon, which drugs, and what payment method J Clin Pharmacol 53 2013 112 117
9. M.S. Cepeda, D. Fife, L. Vo, G. Mastrogiovanni, and Y. Yuan Comparison of opioid doctor shopping for tapentadol and oxycodone: A cohort study J Pain 14 2013 158 164
10. W.M. Compton, and N.D. Volkow Major increases in opioid analgesic abuse in the United States: Concerns and strategies Drug Alcohol Depend 81 2006 103 107
11. Dart R, Bucher-Bartelson B, Adams EH. Non-medical use of tapentadol immediate release by college students. American Academy of Pain Medicine (AAPM) Annual Meeting. Palm Springs, CA. February 2012. http://www.painmed.org/ 2012posters/abstract-271. Accessed May 16, 2013
12. R.C. Dart, T.J. Cicero, H.L. Surratt, A. Rosenblum, B.B. Bartelson, and E.H. Adams Assessment of the abuse of tapentadol immediate release: The first 24 months J Opioid Manag 8 2012 395 402
13. N. Dasgupta, E.J. Bailey, T. Cicero, J. Inciardi, M. Parrino, A. Rosenblum, and R.C. Dart Post-marketing surveillance of methadone and buprenorphine in the United States Pain Med 11 2010 1078 1091
14. F.J. DeFalco, P.B. Ryan, and M.S. Cepeda Applying standardized drug terminologies to observational healthcare databases: A case study on opioid exposure Health Serv Outcomes Res Methodol 13 2013 58 67
15. M.J. Edlund, B.C. Martin, M.Y. Fan, A. Devries, J.B. Braden, and M.D. Sullivan Risks for opioid abuse and dependence among recipients of chronic opioid therapy: Results from the TROUP study Drug Alcohol Depend 112 2010 90 98
16. M.J. Edlund, D. Steffick, T. Hudson, K.M. Harris, and M. Sullivan Risk factors for clinically recognized opioid abuse and dependence among veterans using opioids for chronic non-cancer pain Pain 129 2007 355 362
17. IOM (Institute of Medicine) Relieving pain in America: A blueprint for transforming prevention, care, education, and research 2011 The National Academies Press Washington, DC
18. Large-scale Bayesian logistic regression for text categorization Technometrics 49 2007 291 304
19. H.G. Kress Tapentadol and its two mechanisms of action: Is there a new pharmacological class of centrally-acting analgesics on the horizon? Eur J Pain 14 2010 781 783
20. B.M. Kuehn Opioid prescriptions soar: increase in legitimate use as well as abuse JAMA 297 2007 249 251
21. J. Le Merrer, J.A.J. Becker, K. Befort, and B.L. Kieffer Reward processing by the opioid system in the brain Physiol Rev 89 2009 1379 1412
22. Love LA: Recommendations regarding the abuse potential of tapentadol. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2008/022304s000-OtherR.pdf 2008 Available from: URL: http://www.accessdata.fda.gov/drugsatfda-docs/nda/ 2008/022304s000-OtherR.pdf
23. B.A. Martell, P.G. O'Connor, R.D. Kerns, W.C. Becker, K.H. Morales, T.R. Kosten, and D.A. Fiellin Systematic review: Opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction Ann Intern Med 146 2007 116 127
24. J.A. Myers, J.A. Rassen, J.J. Gagne, K.F. Huybrechts, S. Schneeweiss, K.J. Rothman, M.M. Joffe, and R.J. Glynn Effects of adjusting for instrumental variables on bias and precision of effect estimates Am J Epidemiol 174 2011 1213 1222
25. K.J. O'Malley, K.F. Cook, M.D. Price, K.R. Wildes, J.F. Hurdle, and C.M. Ashton Measuring diagnoses: ICD code accuracy Health Serv Res 40 2005 1620 1639
26. G.L. Peirce, M.J. Smith, M.A. Abate, and J. Halverson Doctor and pharmacy shopping for controlled substances Med Care 50 2012 494 500
27. J.A. Rassen, and S. Schneeweiss Using high-dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system Pharmacoepidemiol Drug Saf 21 Suppl 1 2012 41 49
28. C. Reich, P.B. Ryan, P.E. Stang, and M. Rocca Evaluation of alternative standardized terminologies for medical conditions within a network of observational healthcare databases J Biomed Inform 45 2012 689 696
29. R.C. Rinaldi, E.M. Steindler, B.B. Wilford, and D. Goodwin Clarification and standardization of substance abuse terminology JAMA 259 1988 555 557
30. S. Schneeweiss, J.A. Rassen, R.J. Glynn, J. Avorn, H. Mogun, and M.A. Brookhart High-dimensional propensity score adjustment in studies of treatment effects using health care claims data Epidemiology 20 2009 512 522
31. K.H. Seal, Y. Shi, G. Cohen, B.E. Cohen, S. Maguen, E.E. Krebs, and T.C. Neylan Association of mental health disorders with prescription opioids and high-risk opioid use in US veterans of Iraq and Afghanistan JAMA 307 2012 940 947
32. D. Spence The painful truth: Deaths and misuse of prescribed drugs BMJ 343 2011 d7403
33. E.A. Stuart Matching methods for causal inference: A review and a look forward Stat Sci 25 2010 1 21
34. T. Sturmer, K.J. Rothman, J. Avorn, and R.J. Glynn Treatment effects in the presence of unmeasured confounding: Dealing with observations in the tails of the propensity score distribution - A simulation study Am J Epidemiol 172 2010 843 854
35. Substance Abuse and Mental Health Services Administration. Results from the 2006 national survey on drug use and health: National findings. 2007. Available at: http://www.oas.samhsa.gov/nsduh/2k6nsduh/2k6Results.pdf
36. M.D. Sullivan Limiting the potential harms of high-dose opioid therapy: Comment on "Opioid dose and drug-related mortality in patients with nonmalignant pain." Arch Intern Med 171 2011 691 693
37. Surrat HL, Kurtz SP, Cicero TJ, Dart RC: Street prices of prescription opioids diverted to the illicit market. 12 A.D. Jun 9; 2012
38. D.C. Turk, K.S. Swanson, and R.J. Gatchel Predicting opioid misuse by chronic pain patients: A systematic review and literature synthesis Clin J Pain 24 2008 497 508
39. T.M. Tzschentke, T. Christoph, B. Kogel, K. Schiene, H.H. Hennies, W. Englberger, M. Haurand, U. Jahnel, T.I. Cremers, E. Friderichs, and V.J. De (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): A novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties J Pharmacol Exp Ther 323 2007 265 276
40. N.D. Volkow, and T.A. McLellan Curtailing diversion and abuse of opioid analgesics without jeopardizing pain treatment JAMA 305 2011 1346 1347
41. A.G. White, H.G. Birnbaum, M. Schiller, J. Tang, and N.P. Katz Analytic models to identify patients at risk for prescription opioid abuse Am J Manag Care 15 2009 897 906
42. J. Zacny, G. Bigelow, P. Compton, K. Foley, M. Iguchi, and C. Sannerud College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: Position statement Drug Alcohol Depend 69 2003 215 232
43. X. Zhang, and L. Bao Interaction and regulatory functions of mu- and delta-opioid receptors in nociceptive afferent neurons Neurosci Bull 28 2012 121 130
44. Z. Zhang, and Z.Z. Pan Synaptic mechanism for functional synergism between δ and υ opioid receptors J Neurosci 30 2010 4735 4745